Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997 Feb 15;89(4):1143-6
Date
02/15/1997Pubmed ID
9028935Scopus ID
2-s2.0-0031055374 (requires institutional sign-in at Scopus site) 83 CitationsAbstract
TEL gene rearrangement is the most common genetic lesion in pediatric acute lymphoblastic leukemia (ALL), occurring in about 25% of B-lineage cases. We previously showed that, among patients treated on St Jude protocols, TEL rearrangement independently conferred an excellent prognosis. To extend these results to patients treated with antimetabolite-based therapy, we performed Southern blot analysis to determine the TEL gene status of 104 cases of B-lineage ALL treated on Pediatric Oncology Group 8602, matched on age, gender, and leukocyte count. There were 52 failures among the 77 patients with germline TEL, compared with only 8 failures among 27 patients in the rearranged group. Based on a two-sided logistic regression analysis, stratified for age (subdivided at 10 years), leukocyte count (subdivided at 50,000), and gender, the estimated odds of failing by 4 years in the germline TEL group is 5.4 times that of the rearranged TEL group, with 95% confidence from 1.9 to 15.6, two-sided P = .0009. Thus, the presence of a rearranged TEL gene is also associated with an improved survival among patients treated with antimetabolite-based therapy. Our results indicate that all newly diagnosed ALL patients should be screened for TEL gene rearrangements and suggest that these patients are candidates for less intensive therapy.
Author List
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui CH, Downing JR, Behm FGMESH terms used to index this publication - Major topics in bold
Antimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy Protocols
Asparaginase
Biomarkers, Tumor
Blotting, Southern
Burkitt Lymphoma
Case-Control Studies
Child
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 21
Core Binding Factor Alpha 2 Subunit
Cytarabine
DNA, Neoplasm
Female
Humans
Hydrocortisone
Male
Mercaptopurine
Methotrexate
Neoplasm Proteins
Oncogene Proteins, Fusion
Prednisone
Prognosis
Remission Induction
Retrospective Studies
Single-Blind Method
Translocation, Genetic
Treatment Outcome
Vincristine
